NDA 205382 · Glaxo Grp England
Incruse Ellipta
Umeclidinium Bromide · Inhalation
Last checked: Nov 19, 2026Latest source record: Dec 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Apr 30, 2014
Approved uses
3
Original approval plus efficacy supplements
Registered trials
103
39 Phase 3, 4 recruiting
FAERS reports
9,060
4,828 serious, 661 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 6, 2025.
Umeclidinium ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Umeclidinium ELLIPTA is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1 )
Mechanism: Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 6, 2019 Supplement 10 · Efficacy LetterLabel
- Feb 24, 2016 Supplement 2 · Efficacy LabelLetter
- Apr 30, 2014 Original approval · Type 5 - New Formulation or New Manufacturer Summary ReviewLetterLabel
1 products under this application
- INCRUSE ELLIPTA · UMECLIDINIUM BROMIDE EQ 0.0625MG BASE/INH · POWDER, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Umeclidinium" as an intervention, any sponsor and status, largest first.
GlaxoSmithKlineGSK (GSK)
NCT02164513 · 10,355 participants · Start Jun 30, 2014 · Primary completion Jul 17, 2017
Drug: fluticasone furoate (FF); vilanterol (VI) and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 998 sites in all
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice DesignPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03467425 · 3,109 participants · Start Apr 11, 2018 · Primary completion Oct 10, 2019
Drug: FF/UMEC/VI; Inhaled Corticosteroid and 3 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Aschaffenburg, Germany; Dachau, Germany; Garmisch-Partenirchen, Germany · 143 sites in all
- A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03034915 · 2,696 participants · Start Jun 16, 2017 · Primary completion Jun 18, 2018
Drug: UMEC/VI 62.5/25 mcg via ELLIPTA; UMEC 62.5 mcg via ELLIPTA and 3 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Phoenix, Arizona; Lincoln, California; Clearwater, Florida · 212 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02924688 · 2,436 participants · Start Oct 13, 2016 · Primary completion Feb 22, 2019
Drug: FF/UMEC/VI (100/31.25/25) mcg; FF/UMEC/VI (100/62.5/25) mcg and 6 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 409 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02345161 · 1,811 participants · Start Jan 23, 2015 · Primary completion Apr 1, 2016
Drug: Triple FF/UMEC/VI; Placebo to match FF/UMEC/VI and 3 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Dimitrovgrad, Bulgaria; Lovech, Bulgaria; Pleven, Bulgaria · 159 sites in all
- A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPDPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01313650 · 1,538 participants · Start Mar 1, 2011 · Primary completion Apr 1, 2012
Drug: 62.5/25mcg; 62.5mcg and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Tucson, Arizona; Los Angeles, California; Ormond Beach, Florida · 165 sites in all
- A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPDPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01313637 · 1,493 participants · Start Mar 1, 2011 · Primary completion Mar 1, 2012
Drug: GSK573719/GW642444 125/25mcg; GSK573719 125mcg and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Jasper, Alabama; Phoenix, Arizona; Long Beach, California · 157 sites in all
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled AsthmaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06372496 · 1,358 participants · Start Apr 16, 2024 · Primary completion Jul 28, 2025
Drug: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate; Inhaled corticosteroids/long-acting beta-2 agonists · For: Asthma
Sites: Centreville, Alabama; Little Rock, Arkansas; Newport Beach, California · 117 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,437
- drug ineffective781
- cough735
- asthma640
- pneumonia578
- wrong technique in device usage process547
- chronic obstructive pulmonary disease420
- fatigue392
- product dose omission issue354
- death344
- wheezing341
- headache334
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 99 |
| 2016 | 636 |
| 2017 | 870 |
| 2018 | 1,173 |
| 2019 | 1,241 |
| 2020 | 1,186 |
| 2021 | 767 |
| 2022 | 672 |
| 2023 | 622 |
| 2024 | 679 |
| 2025 | 584 |
| 2026 | 520 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Incruse Ellipta (Umeclidinium Bromide)
2024 spending
$376M
Beneficiaries
185,597
852,329 claims
Per beneficiary
$2,025
$11.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $605,138,195 |
| 2021 | $555,719,848 |
| 2022 | $498,890,589 |
| 2023 | $456,391,929 |
| 2024 | $375,858,548 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Lipson DA, Barnhart F, Brealey N, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA, Barnacle H, Birk R, et al. · Am J Respir Crit Care Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA, Bailes Z, Barnes N, et al. · Lancet Respir Med 2021 · Clinical Trial, Phase III, Comparative Study
- Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study.
Boulet LP, Abbott C, Brusselle G, et al. · J Allergy Clin Immunol Pract 2024 · Research Support, Non-U.S. Gov't, Randomized Controlled Trial
- Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS, Haeussler K, Czira A, et al. · Adv Ther 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial.
Agusti A, Lopez-Campos JL, Miravitlles M, et al. · Arch Bronconeumol 2024 · Multicenter Study, Pragmatic Clinical Trial
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.